CE/CME Statement

Intended Audience
This activity was developed for cardiologists and other health care professionals involved in the care of patients at high risk for cardiovascular disease morbidity and mortality.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

  • Discuss the emerging role of PCSK9 inhibitions in preventive cardiology, specifically in patients at high risk for cardiovascular disease
  • Compare and contrast the efficacy/tolerability profile data, mechanism of action, and administration of emerging PCSK9 inhibitors
  • Identify patients who have unmet cardiopreventive needs and who might benefit from novel, LDL-lowering therapeutic agents

Faculty
Jennifer G. Robinson, MD, MPH
Professor, Departments of Epidemiology and Medicine (Division of Cardiology)
Director, Prevention Intervention Center
University of Iowa
Iowa City, Iowa

Accreditation and Certification
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in this activity. 

Disclosure Statement
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation. 

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or equality in health care and not a specific proprietary business interest of a commercial interest. 

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Jennifer Robinson, MD
               Research Support                     Amarin, Amgen, Astra-Zeneca, Daiichi-Sankyo, Eisai, Glaxo-Smith Kline, Pfizer, Regeneron/Sanofi, Takeda
               
Consultant                               Amgen, Lilly, Merck, Pfizer, Regeneron/Sanofi    

The faculty for this activity have disclosed that there will be discussion about the use of products for non-FDA approved indications.

Additional content planners
The following have no significant relationship to disclose:

Eve Wilson, PhD, ELS, CHCP (medical writer)

Annenberg Center for Health Sciences
John Bayliss, VP, Business Development, spouse is an employee of Amgen, Inc; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

This activity is supported by an educational donation provided by Amgen. 

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the material, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete the activity is 1.0 hour.

Our Policy on Privacy

Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us, or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at http://www.annenberg.net/privacy-policy/.

Contact Information
For help or questions about this Internet activity please contact Continuing Education:
ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone   760-773-4500
Fax       760-773-4513
8 am – 5 pm, Pacific Time, Monday – Friday